Relentlessly focused on advancing the treatment of inflammation and cancer
RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by a bold mission—to treat inflammatory diseases and conquer cancer in our lifetime. Our cutting-edge science is fully focused on developing oral therapeutics that intelligently target key drivers of the immune system to transform the treatment of inflammation and cancer, and improve and empower countless lives. Join us in our quest.
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
March 07, 2024
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 05, 2024
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
You are leaving RAPT.com to go to the eczema clinical trial study site.